Abstract
With dopaminergic systems, non dopaminergic neurotransmission probably plays a major role in parkinsonian syndromes (Multiple System Atrophy, Progressive Supranuclear Palsy, Pure Autonomic Failure, Cortical basal degeneration, Lewy Body Disease). A better understanding of the pathophysiology of these syndromes led to the development of molecules that interact with non dopaminergic systems. Thus, freezing, gait and balance disorders, dysautonomia and neuropsychiatric disorders are likely to benefit from specific treatments. However, due to methodological difficulties related to the evaluation of such molecules, controlled trials are rather rare and the results are often partial and sometimes unclear.
MeSH terms
-
Anti-Dyskinesia Agents / therapeutic use*
-
Botulinum Toxins / therapeutic use*
-
Cholinesterase Inhibitors / therapeutic use*
-
Clozapine / therapeutic use*
-
Dementia / drug therapy*
-
Dementia / etiology*
-
Depressive Disorder / drug therapy*
-
Depressive Disorder / etiology*
-
Dopamine / metabolism*
-
Glutamic Acid / metabolism
-
Humans
-
Movement Disorders / diagnosis
-
Movement Disorders / drug therapy*
-
Movement Disorders / etiology
-
Parkinsonian Disorders / complications*
-
Parkinsonian Disorders / diagnosis
-
Parkinsonian Disorders / metabolism*
-
Selective Serotonin Reuptake Inhibitors / therapeutic use*
-
Serotonin / metabolism
-
Synaptic Transmission / physiology
-
Treatment Outcome
Substances
-
Anti-Dyskinesia Agents
-
Cholinesterase Inhibitors
-
Serotonin Uptake Inhibitors
-
Serotonin
-
Glutamic Acid
-
Botulinum Toxins
-
Clozapine
-
Dopamine